Polish Stem Cells Bank (PBKM)/ FamiCord Group

famicord.eu

The Polish Stem Cells Bank (PBKM) is operating on the international market under the brand of FamiCord Group, which was founded in 2002. It is a stem cell bank, engaged in the acquisition, processing and long-term storage of stem cells taken from umbilical cord blood and other fetal tissues on behalf of parents – family banking. The aim of PBKM is to ensure access of the family for stem cells in case of need for therapy. As of 2017 FamiCord has released more than 30 units of cord blood for transplantatation and more than 1000 units of stem cells from other sources. Currently Famicord Group operates directly in Poland, Spain, Turkey, Latvia, Hungary, Romania, Italy and through business partners in Sweden, Ukraine, Serbia and UK .

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

news image

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More

AIKIDO PHARMA EXECUTES ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING RESEARCH AGREEMENT WITH COGIA BIOTECH LTD

AIkido Pharma | May 06, 2020

news image

AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research. Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development. Cogia provides state-of-the-art digital information and dis...

Read More

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

MEDICAL

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

news image

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More
news image

MEDICAL

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More
news image

AIKIDO PHARMA EXECUTES ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING RESEARCH AGREEMENT WITH COGIA BIOTECH LTD

AIkido Pharma | May 06, 2020

AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research. Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development. Cogia provides state-of-the-art digital information and dis...

Read More
news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More
news image

MEDICAL

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More